Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ET-501
- Development stage
- Preclinical
- Lead developer
- Expression Therapeutics
- Modality
- Native Immune Cells → Adoptive Cell Transfer → Cell Therapies, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
ET-501 (ADEPT-STAR-NET-1) is an autologous gamma delta T cell therapy combined with a bispecific T cell engager (BiTE) developed by Expression Therapeutics for the treatment of neuroendocrine tumors (NETs). The therapy targets Somatostatin Receptor 2 (SSTR2), which is frequently overexpressed in NETs, and CD3 on the surface of T cells. By utilizing gamma delta T cells—which possess innate-like anti-tumor properties and do not require MHC-restricted antigen presentation—and redirecting them via the bispecific engager, ET-501 aims to enhance the precision and potency of T cell-mediated cytotoxicity against SSTR2-expressing tumor cells.
- Other names
- SSTR2-CD3ε γδ T cell therapyLENTeT SSTR2-CD3ε
02
Targets
CD3 (T-cell surface glycoprotein CD3)SSTR2 (Somatostatin receptor type 2)
Beyond the preview
Go deeper on ET-501.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ET-501.